SCHEMBL2843090

SCHEMBL2843090

Nc1nc2cccc(CC3CCCCC3)c2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ APP P05067 1/20 0.40
▸ FBP1 P09467 2/20 0.39
▸ POLB P06746 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ PDE4A P27815 2/20 0.37
▸ PDE4B Q07343 2/20 0.37
▸ PDE4C Q08493 2/20 0.37
▸ PDE4D Q08499 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ ASH1L Q9NR48 1/20 0.36
▸ PNP P00491 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843088 0.78 ALDH1A1 (0.46) HTR1ADRD2HTR2AFBP1POLB
SCHEMBL23422372 0.74 ELANE (0.44) HTR1ADRD2HTR2AGAARAB9A
SCHEMBL2335323 0.72 DRD2 (0.46) HTR1ADRD2HTR2ARAB9AALDH1A1
SCHEMBL25801523 0.72 DRD2 (0.46) HTR1ADRD2HTR2AFBP1GAA
SCHEMBL20982254 0.70 ATM (0.40) RAB9AALDH1A1ATMKDM4EMEN1
SCHEMBL5744913 0.69 CEL (0.39) GAARAB9AALDH1A1PNPATM
SCHEMBL20568006 0.69 KDM4E (0.43) APPGAARAB9AALDH1A1PNP
SCHEMBL9373695 0.69 KDM4E (0.43) APPGAARAB9AALDH1A1PNP
SCHEMBL8786337 0.69 KDM4E (0.43) APPGAARAB9AALDH1A1PNP
SCHEMBL2150813 0.69 KDM4E (0.43) APPGAARAB9AALDH1A1PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018081276-A1 COMPOUNDS TESARO, INC. (US) 2018-05-03 — — WO claimed
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 — — EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
EP-2152700-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE Novartis Ag (CH) 2010-02-17 — — EP disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 HTR1A 3620/4885DRD2 4738/4885HTR2A 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback